Automated Staining Aids Real-Time Tumor Calls - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Automated Staining Aids Real-Time Tumor Calls

Automated frozen-section staining helped classify selected ambiguous tumors and margins in a single-center validation study.

  • By

  • Andrea Surnit

  • May 11, 2026

  • 3 min

Share

Clinical Scorecard: Automated Staining Aids Real-Time Tumor Calls

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients undergoing intraoperative frozen-section assessment for various tumor types.
Care Setting

Key Highlights

  • FFRA-IHC improved classification in 68% of previously unclassifiable tumors, including carcinomas and lymphomas.

Guideline-Based Recommendations

Diagnosis

  • Utilize FFRA-IHC for rapid classification of ambiguous tumors.
  • Conduct larger studies to validate the effectiveness of FFRA-IHC.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        FFRA-IHC can redirect management from surgical to hematologic evaluation by providing rapid classification.

        Clinical Best Practices

        • Communicate initial frozen-section diagnosis before initiating FFRA-IHC.
        • Consider the limitations of the antibody panel when interpreting results, especially in ambiguous cases.

        Related Resources & Content

        Original Source(s)

        Automated Staining Aids Real-Time Tumor Calls

        • by Andrea Surnit

        • May 11, 2026

        Related Content

        Retained silk may underlie late postvasectomy fistula

        Surgery and histopathology identified retained silk ligature with chronic inflammation at the site of a rare fistula presenting 3 years following vasectomy.

        Educators weigh how to use AI without losing critical thinking

        Greater productivity is not necessarily indicative of greater knowledge.

        FDA expands essential thrombocythemia care

        Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.